August 26, 2015
Molecular Tumor Board Meetings, held at UC San Diego Moores Cancer Center, bring together physicians caring for patients with cancer and other providers to discuss specific patients and advise one another on the best treatment plans.
Under the direction of Razelle Kurzrock, MD, UC San Diego Health and Moores Cancer Center have initiated a new, leading-edge type of tumor board that discusses patients with all types of cancer whose tumors have been analyzed with advanced genomic diagnostic tests. This new Molecular Tumor Board, working with the Center for Personalized Cancer Therapy, enables to translate the strong science at UC San Diego Health into recommendations for individual patient treatments.
The Molecular Tumor Board includes expert physicians and world-class scientists, including medical oncologists, surgeons, radiation therapists, researchers, geneticists and pathologists. Dr. Messmer had the opportunity to discuss the importance of biologic drug dose monitoring and to present Abreos' technology and applications for point-of-care testing.
Bradley Messmer, founder and CEO of Abreos Biosciences, is speaking at the Molecular Tumor Board Meeting about precision dosing of biologic drugs and point-of-care testing